Mineralys Therapeutics, Inc.

MLYS Healthcare Biotechnology

In the quarter to June 2026, EPS fell 331.8% and free cash flow fell 7.91%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

20.30 1.34 −6.19%
Market cap
$1.9B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Current Ratio

+8 more quarters

25.50 43.76 44.33 34.46
Net Debt/EBITDA
14.44 17.16 14.25 2.29
Debt/Equity
0.00 0.00 0.00 0.18
Free Cash Flow per Share
(0.41) (0.56) (0.48) (0.38)
Book value per Share
8.17 9.56 7.70 6.50
Free Cash Flow
(28.87) (37.90) (39.47) (32.56)
Other line items

Show all line items

Columns are period end dates